8-K: Health In Tech Secures $3M Via Equity Purchase Agreement

Health In Tech, Inc. has completed a second closing under its Standby Equity Purchase Agreement, receiving $3 million in gross proceeds through a promissory note.

Summary

• Health In Tech, Inc. (the Company) has completed a second closing under its Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. (the Investor).
• This second closing, referred to as the Second Pre-Paid Advance Closing, occurred on November 2, 2026.
• The Company issued a second Promissory Note to the Investor for $3.0 million, resulting in gross proceeds of $2.85 million after a 5% discount.
• This $3.0 million note is in addition to a $7.0 million note issued on August 18, 2026, bringing the total principal of the Promissory Notes to $10.0 million.
• The Promissory Notes mature on February 18, 2028, and bear interest at 8.75% per annum, which can increase to 18% upon certain events of default.
• Installment payments on the notes can be made in cash or with net proceeds from Class A Common Stock sales under the SEPA.
• The Investor has the option to convert the Promissory Notes into Class A Common Stock at a fixed price of $1.5735 per share, subject to limitations.
• These limitations include a 4.99% beneficial ownership cap and an Exchange Cap of 13,100,378 shares (approximately 19.99% of outstanding stock) without stockholder approval.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to the dilutive nature of the financing and the company's reliance on debt instruments with potentially unfavorable terms.

Positives

• Secured $2.85 million in gross proceeds from the second closing, providing immediate capital.
• The SEPA and Registration Rights Agreement provide a framework for future equity financing if needed.
• The company has a clear path to potentially raise additional capital through the SEPA, subject to limitations.

Negatives

• The $3.0 million promissory note was issued at a 5% discount, reducing the net proceeds to $2.85 million.
• The Promissory Notes carry a significant interest rate of 8.75%, potentially increasing to 18% upon default.
• The notes are subject to a 4% payment premium if not settled by stock sales.
• The fixed conversion price of $1.5735 per share may be significantly higher than the market price, leading to dilution.
• The company is seeking stockholder approval to issue shares exceeding the Exchange Cap, indicating potential future dilution beyond the initial 19.99% limit.
• The reliance on debt financing and potential equity dilution suggests ongoing financial challenges.

Risks

• Potential for significant dilution of existing shareholders if the Investor converts the Promissory Notes into Class A Common Stock.
• The interest rate on the Promissory Notes can escalate to 18% upon certain events of default, increasing the company's debt burden.
• Failure to obtain stockholder approval for issuing shares beyond the Exchange Cap could limit future financing options.
• The company's ability to repay the Promissory Notes depends on its operational performance and ability to generate cash or sell stock.
• Market price fluctuations of Class A Common Stock could impact the attractiveness and terms of future equity sales under the SEPA.

Future Outlook

The company is seeking stockholder approval at its November 10, 2026 annual meeting to issue shares exceeding the current Exchange Cap, which is necessary for potential future financing under the SEPA beyond the 19.99% limit. The Promissory Notes mature on February 18, 2028, and their repayment or conversion will depend on the company's financial performance and stock price.

Management Comments

• The company is seeking stockholder approval of the issuance of shares in excess of the Exchange Cap at its annual meeting of stockholders scheduled for November 10, 2026.

Industry Context

StockSavvy.ai notes that this type of standby equity purchase agreement and associated debt financing is often utilized by companies, particularly in the technology and healthcare sectors, facing capital needs and seeking flexibility. However, the terms, including discounts and interest rates, can be indicative of the company's perceived risk profile by investors.

Stakeholder Impact

• Shareholders: Potential for significant dilution if the Investor converts the Promissory Notes into Class A Common Stock, especially if stockholder approval is granted to exceed the Exchange Cap.
• Creditors: The company's increased debt burden from the Promissory Notes could impact its creditworthiness and ability to secure future financing.
• Management: Faces the challenge of managing debt obligations and seeking stockholder approval for potentially dilutive share issuances.

Next Steps

• The company will hold its annual meeting of stockholders on November 10, 2026, to seek approval for issuing shares in excess of the Exchange Cap.
• The Investor may convert the Promissory Notes into Class A Common Stock, subject to limitations.
• The Promissory Notes mature on February 18, 2028.

Key Dates

Recommendation

The company has secured necessary funding, but the terms of the financing (discounted note, high potential interest rate, and significant dilution risk) indicate financial strain. While the capital infusion is positive, the ongoing need for such financing and the potential for substantial dilution warrant a cautious 'hold' stance until operational improvements and a clearer path to profitability are demonstrated.

Keywords

Standby Equity Purchase Agreement, Promissory Note, Capital Raise, Equity Financing, SEC Filing, Form 8-K, Health In Tech, YA II PN, Ltd.